Skip to content

Acadia Pharmaceuticals ACAD Increase (Decrease) in Accounts Receivable and Other Operating Assets

Increase (Decrease) in Accounts Receivable and Other Operating Assets at other companies

TFS Financial logo
TFS FinancialTFSL
-$142K
TRG
Targa ResourcesTRGP
$198M+191%
Realty Income logo
Realty IncomeO
$114.38M+19.9%
NXP Semiconductors logo
NXP SemiconductorsNXPI
$115M+297%
Cherry Hill Mortgage Investment logo
Cherry Hill Mortgage InvestmentCHMI
-$2.55M-3.4%
Ferguson Enterprises logo
Ferguson EnterprisesFERG
$275M+127%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets?
Acadia Pharmaceuticals (ACAD) reported increase (decrease) in accounts receivable and other operating assets of -$13.74M in Q1 2026.
How has Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets changed year-over-year?
Acadia Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets decreased by 781.9% year-over-year, from $2.02M to -$13.74M.